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Poster Presentations: Saturday, July 21, 2018 P167specifically targeted for hippocampal subfield morphometry. The
strong relationship between AV1451 tau uptake and CA1 atrophy
in Ab negative individuals suggests that AV1451 PET may be sen-
sitive to the tau pathology of PART, which, in turn, drivesMTL neu-
rodegeneration and perhaps the cognitive symptoms of those in this
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Boston, MA, USA. Contact e-mail: dutta.joyita@mgh.harvard.eduBackground: Differential measurement of tau aggregates in the
brain using serial PET imaging is of great significance in image-
based biomarker development for aging and Alzheimer’s disease.
However, partial volume effects arising from the limited spatial res-
olution of PET pose a challenge to quantitation.We have developed
an image deblurring technique that utilizes high-resolution anatom-
ical information to correct for partial volume effects in differential
images of tau based on serial [18F]Flortaucipir PET datasets.
Methods: The deblurring technique is based on 1) deconvolution
of co-registered difference images using the point spread function
of the scanner measured in the image space and 2) minimization
of the joint entropy between the PET difference image and a co-
registered T1-weighted MPRAGE MR image. Serial [18F]Flortau-
cipir ([18F]AV1451) PET data was acquired from an elderly cohort
(63-90 years) consisting of 96 Harvard Aging Brain Study partici-
pants. The time gap between baseline and follow-up scans was 0.6-
3.6 years.Results:As shown in Fig. A, deblurring led to successfully
recovery of structural details in the PET difference images while
suppressing spurious negative values due to noise. Annualized rates
of change based on standardized uptake value ratio (SUVR) differ-ges: Transverse slices from a subject showing the ROI labels,
tion TI MR image, the uncorrected PET SUVR difference
e jointly deblurred PET (dbPET) SUVR difference image.
ls include inferior temporal cortex (ITC), fusiform gyrus
ocampal gyrus (PHG), and entorhinal cortex (EC).
UVR - Annualized Change: dbPET led to non-negative mea-
ced standard deviation relative to the original PET difference
of Variation: dbPET generated reduced coefficients of varia-
oth cognitively normal and impaired cohorts.
Sample Size: The reduction in CV translates to a dramatic
e minimum required sample size for a given effect size.ences across the two timepoints were computed corresponding to
the following 4 clinically relevant regions-of-interest (ROIs): infe-
rior temporal cortex (ITC), fusiform gyrus (FG), parahippocampal
gyrus (PHG), and entorhinal cortex (EC), as shown in Fig. B. We
used the coefficient of variation (CV) or relative standard deviation
as a measure of biomarker reliability. As shown in Fig. C, deblur-
ring led to prominent reductions in CV for all ROIs for both cogni-
tively normal and impaired cohorts. Importantly, this translated to
much smaller samples needed to detect an effect of given size as
illustrated in Fig. D. Conclusions:Joint deblurring of serial datasets
led to reduced CV levels and smaller sample size requirements.
This finding is particularly critical in the context of drug develop-
ment as it indicates lower sample sizes required to detect a drug-
induced lowering of tau pathology. Thus, our deblurring approach
shows promise in the development of novel tau-based quantitative
biomarkers for aging and Alzheimer’s disease.IC-P-204 THE RELATIONSHIP BETWEEN TAU PETAND OTHER AD BIOMARKERS IN
AUTOSOMAL DOMINANTALZHEIMER
DISEASEBrian A. Gordon1,2, Tyler Blazey3, Jon Christensen3, Shaney Flores1,
Aylin Dincer3, Sarah Keefe1, Eric McDade2, Guoqiao Wang3,
Marcus E. Raichle3, Bob Koeppe4, Clifford R. Jack, Jr.5, John C. Morris6,
Randall J. Bateman7, Tammie L. S. Benzinger3, and the Dominantly
Inherited Alzheimer’s Network, 1Washington University in St. Louis School
of Medicine, St. Louis, MO, USA; 2Knight Alzheimer’s Disease Research
Center, St. Louis, MO, USA; 3Washington University School of Medicine,
St. Louis, MO, USA; 4University of Michigan, Ann Arbor, MI, USA; 5Mayo
Clinic, Rochester, MN, USA; 6Washington University School of Medicine,
Saint Louis, MO, USA; 7Washington University, St. Louis, MO, USA.
Contact e-mail: bagordon@wustl.edu
Background: In autosomal dominant Alzheimer disease (ADAD),
there is a conservation of age of symptom onset within families.
This consistency allows participants to be staged according to their
estimated years to symptom onset (EYO). This provides an elegant
model to study the emergence of AD biomarkers during the transi-
tion from preclinical to clinical stages of the disease. ADAD co-
horts also provide robust populations of mutation carriers with
preclinical and clinical AD as well as familial controls that are mu-
tation non-carriers. Methods:ADAD participants were drawn from
families known to have mutations in presenilin 1, presenilin 2, and
amyloid precursor protein genes. The cohort consisted of 16 muta-
tion non-carriers (NC), 20 asymptomatic carriers (aMC, CDR¼0),
and 15 symptomatic carriers (sMC: 13 CDR 0.5, 1 CDR¼1, 1
CDR¼3). Participants had tau (flortaucipir), beta-amyloid (PiB),
and metabolic imaging (FDG) PET imaging as well as structural
MRI. Voxel-wise PET data were nonlinearly aligned to the
MNI152 atlas using a two-stage registration. Voxel-wise statistics
were performed comparing groups using permutation testing.
Data were additionally analyzed using regions of interest derived
from Freesurfer. Primary comparisons were between NC, aMC,
and sMC groups. Results: All four modalities showed significant
group effects, with worse AD pathology in the sMC individuals
relative to both the aMC and NC groups (Figures 1-4). There was
a clear spatial overlap in what regions of the brain were affected
by pathology, with a common focus in the precuneus and lateral pa-
rietal regions. There was a prominent cross-modal relationship be-
tween tau and the other three biomarkers. For the entire sample
there was a significant correlation between precuneus tau and PiB
(r¼0.73, p¼0.000000004), FDG (r¼-0.63, p¼0.002), and cortical
thickness (r¼-0.69, p¼0.00000003). The strength of these
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inent in the sMCs. Conclusions:We found overlapping spatial pat-
terns of biomarker change in ADAD, with pathological changes
consistently located in the precuneus and lateral parietal regions
across all four biomarkers. The degree of beta-amyloid, hypome-tabolism, and cortical thinning were all strongly correlated with
tau pathology measured with flortaucipir.IC-P-205 LONGITUDINALTAU-PETAND ATROPHYIN HEALTHYOLDER ADULTS AND THOSE
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with Alzheimer’s disease (AD). The rate of tau accumulation in
healthy older adults and patients with AD is not well described,
nor is the relationship of tau accumulation to cortical atrophy.
Methods: We used AV1451-PET to interrogate tau accumulation
over time in healthy older adults (OA; n¼34) and patients with
probable AD (n¼12; Table 1). AV1451 images were normalized
by cerebral white matter and preprocessed using a longitudinal
pipeline. ROI analyses were also performed using partial volume
correction (PVC; Rousset method) and annual percent change
(APC) was calculated for mean PVC SUVR values in regions cor-
responding to Braak stages. Linear mixed effects models were used
to predict AV1451 change in Braak regions. Structural MRI scans
were processed for longitudinal VBM. PiB-PET scans were used
to determine amyloid burden. Results: One sample t-tests on
AV1451-APC in OA showed significant increases at follow-up in
each Braak stage (Braak I/II mean AV1451-APC¼2.37%; Braak
III/IV AV1451-APC¼2.82%; Braak V/VI AV1451-APC¼2.79%,
all p<0.001; Fig.1). There were no differences in AV1451-APC
or in rate of AV1451 change based on PiB status in OA. Mixed
effects models showed significant differences in AV1451 change
over time between AD and OA in Braak III/IV (mean AD
